Pharma channel feed

FDA+ roundup: Agency re­opens AI dis­cus­sion pa­per for com­ments amid two-day work­shop

Last year
AI
FDA+

Cost-ef­fec­tive­ness of Mer­ck’s po­ten­tial hy­per­ten­sion drug will hinge on long-term da­ta, ICER says

Last year

How Tik­Tok’s al­go­rithm and au­di­ences are fi­nal­ly con­vinc­ing Big Phar­ma to join

Last year
Marketing

Mar­ket­ingRx roundup: Phar­ma in­dus­try rep drops in Gallup poll; Pfiz­er web­site re­veals not-yet-ap­proved drug name

Last year
Marketing

Bris­tol My­ers joins As­traZeneca in agree­ing to drug price ne­go­ti­a­tion terms ahead of first dead­line

Last year
Law

No­vo Nordisk forms car­diometa­bol­ic drug dis­cov­ery ac­cel­er­a­tor to get to re­search faster

Last year

Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

Last year
Deals

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

Last year
Deals
R&D

CDC ad­vi­sors rec­om­mend Pfiz­er's ma­ter­nal RSV vac­cine in 11-1 vote

Last year
FDA+

Ozem­pic sales surge could con­tin­ue in­to 2024, re­searchers say

Last year
Marketing

Boehringer In­gel­heim, Eli Lil­ly clinch new FDA ap­proval for block­buster Jar­diance to treat chron­ic kid­ney dis­ease

Last year
FDA+

Sen­a­tors call on FDA to not risk bi­as­ing study find­ings in fa­vor of opi­oid use

Last year

Dex­com re­cruits new class of col­lege ath­letes with type 1 di­a­betes for spon­sor­ship deals

Last year
Marketing

FDA ad­vi­sors unan­i­mous­ly re­ject Intar­ci­a's em­bat­tled type 2 di­a­betes treat­ment

Last year
FDA+

Roche scru­ti­nized by UK watch­dog over 'mis­lead­ing' Ro­z­lytrek pro­mo­tion­al web­site

Last year
Marketing

GE Health­Care hits the road in a health tech bus to bring its lat­est so­lu­tions to hos­pi­tal doorsteps

Last year
Marketing

GSK's Vi­iV Health­care takes Shut­ter­stock-part­nered cam­paign in new di­rec­tion

Last year
Marketing

Ex­clu­sive: As­traZeneca signs off on a ‘car­bon neg­a­tive’ new biotech build­ing for one of its lat­est buy­outs

Last year
Bioregnum

No­vo Nordisk’s US semaglu­tide man­u­fac­tur­ing site un­der the spot­light again as 2022 mon­i­tor­ing is­sue sur­faces

Last year
Manufacturing

Physi­cians see ‘new era for weight loss med­ica­tions’ with the ar­rival of No­vo, Lil­ly GLP-1 meds, sur­vey says

Last year
Marketing

Ac­tor Er­ic Ston­estreet talks about his re­al 'mod­ern fam­i­ly' in aware­ness cam­paign for eye dis­ease

Last year
Marketing

Mod­er­na de­creas­es mR­NA pro­duc­tion with Lon­za in Switzer­land, brings some man­u­fac­tur­ing in-house

Last year
Manufacturing

In­cyte ad­vances its Opzelu­ra eczema cam­paign with a ‘reimag­ine’ theme  

Last year
Marketing

Elon Musk's brain-com­put­er pro­gram be­gins re­cruit­ing paral­y­sis pa­tients

Last year
R&D
FDA+
First page Previous page 100101102103104105106 Next page Last page
A service from the Financial Times